It has been established that patients with primary breast tumours expressing a high level of p130Cas/BCAR1 protein, experience more rapid disease recurrence and are at a higher risk for intrinsic resistance to tamoxifen therapy (van der Flier et al, 2000; Cabodi et al, 2004). Here, BCAR1 is linked to breast neoplasm.